Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea
Michinori Ogura, Won-Seog Kim, Toshiki Uchida, Naokuni Uike, Youko Suehiro, Kenichi Ishizawa, Hirokazu Nagai, Fumiko Nagahama, Yusuke Sonehara, Kensei Tobinai, Michinori Ogura, Won-Seog Kim, Toshiki Uchida, Naokuni Uike, Youko Suehiro, Kenichi Ishizawa, Hirokazu Nagai, Fumiko Nagahama, Yusuke Sonehara, Kensei Tobinai
Abstract
Objective: Two phase I studies of darinaparsin including Japanese and Korean patients with relapsed/refractory peripheral T-cell lymphoma were performed to evaluate its safety (primary purpose), efficacy and pharmacokinetic profile (ClinicalTrials.gov: NCT01435863 and NCT01689220).
Methods: Patients received intravenous darinaparsin for 5 consecutive days at 200 mg/m2/day in 4-week cycles, 300 mg/m2/day in 4-week cycles or 300 mg/m2/day in 3-week cycles.
Results: Seventeen Japanese and 6 Korean patients were enrolled and treated. Drug-related adverse events developed in 18 patients (78%). Dose-limiting toxicity, grade 3 hepatic dysfunction, was reported on Day 15 of cycle 1 in 1 Japanese patient who received 300 mg/m2/day. The most common drug-related, grade ≥ 3 adverse events were lymphopenia (9%), neutropenia (9%) and thrombocytopenia (9%). No deaths occurred. In 14 evaluable patients, 1 and 3 patients had complete response and partial response, respectively. The plasma concentration-time profiles of arsenic, a surrogate marker for darinaparsin, were similar between Japanese and Korean patients. No significant difference was found in its pharmacokinetic profile.
Conclusions: These data indicate the good tolerability and potential efficacy of darinaparsin in patients with relapsed/refractory peripheral T-cell lymphoma. Darinaparsin 300 mg/m2/day for 5 consecutive days in 3-week cycles is the recommended regimen for phase II study.
Keywords: Asia; darinaparsin; peripheral T-cell lymphoma; pharmacokinetics; phase I.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures
References
- Dearden CE, Johnson R, Pettengell R et al. British Committee for Standards in Haematology. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011;153:451–85.
- Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011;117:6756–67.
- Vose J, Armitage J, Weisenburger D. International T-cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–30.
- Weisenburger DD, Savage KJ, Harris NL et al. International peripheral T-cell lymphoma project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood 2011;117:3402–8.
- Mak V, Hamm J, Chhanabhai M et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31:1970–6.
- Ogura M, Ishida T, Hatake K et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014;32:1157–63.
- Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–6.
- Horwitz S, O’Connor OA, Pro B et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 2019;393:229–40.
- Coiffier B, Pro B, Prince HM et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631–6.
- O’Connor OA, Horwitz S, Masszi T et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 2015;33:2492–9.
- O’Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182–9.
- Tsukasaki K, Tobinai K, Uchida T et al. Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL). J Clin Oncol 2016;2016:34.
- Diaz Z, Mann KK, Marcoux S et al. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia 2008;22:1853–63.
- Mann KK, Wallner B, Lossos IS, Miller WH Jr. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs 2009;18:1727–34.
- Hussein MA Trials of arsenic trioxide in multiple myeloma. Cancer Control 2003;10:370–4.
- List A, Beran M, DiPersio J et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003;17:1499–507.
- Hermine O, Dombret H, Poupon J et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004;5:130–4.
- Tsimberidou AM, Camacho LH, Verstovsek S et al. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res 2009;15:4769–76.
- Berenson JR, Jaganath S, Reece D et al. ZIO-101 (S-dimethylarsinoglutathione): phase I/II trials in advanced/progressive multiple myeloma. J Clin Oncol 2007;25:8109.
- Wu J, Henderson C, Feun L et al. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs 2010;28:670–6.
- Hosein PJ, Craig MD, Tallman MS et al. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. Am J Hematol 2012;87:111–4.
- Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press, 2008.
- Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) (31 January 2012, date last accessed).
- Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.
- Zettl A, Lee SS, Rüdiger T et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002;117:368–79.
- Willenbrock K, Bräuninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol 2007;138:733–9.
- Yang QX, Pei XJ, Tian XY et al. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature. Diagn Pathol 2012;7:7.
- Mathieu D, Mathieu-Nolf M, Germain-Alonso M, Neviere R, Furon D, Wattel F. Massive arsenic poisoning-effect of hemodialysis and dimercaprol on arsenic kinetics. Intensive Care Med 1992;18:47–50.
- Ohnishi K, Yoshida H, Shigeno K et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002;16:617–22.
- Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003;21:3609–15.
Source: PubMed